{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:12:21Z","timestamp":1771866741016,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ccm.2015.11.005","type":"journal-article","created":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T02:46:45Z","timestamp":1450838805000},"page":"139-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Using Cystic Fibrosis Therapies for Non\u2013Cystic Fibrosis Bronchiectasis"],"prefix":"10.1016","volume":"37","author":[{"given":"Wael","family":"ElMaraachli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas J.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela C.C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2015.11.005_bib1","doi-asserted-by":"crossref","first-page":"e71109","DOI":"10.1371\/journal.pone.0071109","article-title":"Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends","volume":"8","author":"Ringshausen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ccm.2015.11.005_bib2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1378\/chest.11-2209","article-title":"Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007","volume":"142","author":"Seitz","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2015.11.005_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.cpm.0000171422.98696.ed","article-title":"Prevalence and economic burden of bronchiectasis","volume":"12","author":"Weycker","year":"2005","journal-title":"Clin Pulm Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1465-9921-13-21","article-title":"Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients","volume":"13","author":"Goeminne","year":"2012","journal-title":"Respir Res"},{"key":"10.1016\/j.ccm.2015.11.005_bib5","first-page":"6","article-title":"Inflammation: a two-edged sword\u2013the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur J Respir Dis Suppl"},{"key":"10.1016\/j.ccm.2015.11.005_bib6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1183\/09031936.00069007","article-title":"Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms","volume":"31","author":"Fuschillo","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2015.11.005_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1165\/ajrcmb\/4.1.26","article-title":"Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium","volume":"4","author":"Amitani","year":"1991","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ccm.2015.11.005_bib8","first-page":"L835","article-title":"Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells","volume":"276","author":"Voynow","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ccm.2015.11.005_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/thx.2010.142778","article-title":"British thoracic society non-CF bronchiectasis guideline group. British Thoracic Society guideline for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2015.11.005_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1378\/chest.11-1024","article-title":"Bronchiectasis in a diverse us population: effects of ethnicity on etiology and sputum culture","volume":"142","author":"McShane","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2015.11.005_bib11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1164\/ajrccm.162.4.9906120","article-title":"An investigation into causative factors in patients with bronchiectasis","volume":"162","author":"Pasteur","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.rmed.2006.11.008","article-title":"Aetiology in adult patients with bronchiectasis","volume":"101","author":"Shoemark","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib13","first-page":"1159","article-title":"Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance?","volume":"52","author":"Restrepo","year":"2007","journal-title":"Respir Care"},{"key":"10.1016\/j.ccm.2015.11.005_bib14","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1378\/chest.99.5.1088","article-title":"A\u00a0controlled trial of long-term bronchodilator therapy in cystic fibrosis","volume":"99","author":"Eggleston","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2015.11.005_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1378\/chest.11-0180","article-title":"Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis","volume":"141","author":"Mart\u00ednez-Garc\u00eda","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2015.11.005_bib16","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00003495-200767070-00002","article-title":"Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?","volume":"67","author":"King","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ccm.2015.11.005_bib18","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis","volume":"132","author":"Mart\u00ednez-Garc\u00eda","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2015.11.005_bib19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJM200003233421204","article-title":"Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis","volume":"342","author":"Lai","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib20","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199503303321303","article-title":"Effect of high-dose ibuprofen in patients with cystic fibrosis","volume":"332","author":"Konstan","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jpeds.2007.04.009","article-title":"High-dose ibuprofen in cystic fibrosis: Canadian Safety and Effectiveness Trial","volume":"151","author":"Lands","year":"2007","journal-title":"J\u00a0Pediatr"},{"issue":"4","key":"10.1016\/j.ccm.2015.11.005_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007525.pub2","article-title":"Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis","author":"Pizzutto","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ccm.2015.11.005_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1183\/09031936.00042208","article-title":"Long-term macrolide therapy in chronic inflammatory airway diseases","volume":"33","author":"Crosbie","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2015.11.005_bib24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ppul.20620","article-title":"Clinical response to azithromycin in cystic fibrosis correlates with in\u00a0vitro effects on Pseudomonas aeruginosa phenotypes","volume":"42","author":"Nguyen","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ccm.2015.11.005_bib25","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic Fibrosis Foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ccm.2015.11.005_bib26","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2015.11.005_bib27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2015.11.005_bib28","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet (London England)"},{"key":"10.1016\/j.ccm.2015.11.005_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ismej.2014.124","article-title":"Predominant pathogen competition and core microbiota divergence in chronic airway infection","volume":"9","author":"Rogers","year":"2015","journal-title":"ISME J"},{"key":"10.1016\/j.ccm.2015.11.005_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/thoraxjnl-2014-205826","article-title":"Respiratory microbiota: addressing clinical questions, informing clinical practice","volume":"70","author":"Rogers","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2015.11.005_bib31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2012-203105","article-title":"Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition","volume":"68","author":"Rogers","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2015.11.005_bib32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1513\/AnnalsATS.201310-339FR","article-title":"Lung microbiome for clinicians. New discoveries about bugs in healthy and diseased lungs","volume":"11","author":"Segal","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ccm.2015.11.005_bib33","first-page":"18","article-title":"Influence of Pseudomonas aeruginosa on exacerbation in patients with bronchiectasis","volume":"7","author":"Chawla","year":"2015","journal-title":"J\u00a0Glob Infect Dis"},{"key":"10.1016\/j.ccm.2015.11.005_bib34","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2007.03.009","article-title":"Microbiologic follow-up study in adult bronchiectasis","volume":"101","author":"King","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.rmed.2011.11.018","article-title":"Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis","volume":"106","author":"White","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib36","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1128\/AAC.45.12.3468-3473.2001","article-title":"Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis","volume":"45","author":"Montgomery","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ccm.2015.11.005_bib37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2015.11.005_bib38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non\u2013cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib39","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2012.03.010","article-title":"A\u00a0network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis","volume":"11","author":"Littlewood","year":"2012","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.ccm.2015.11.005_bib40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib41","doi-asserted-by":"crossref","first-page":"114S","DOI":"10.1378\/chest.120.3_suppl.114S","article-title":"Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa","volume":"120","author":"Couch","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2015.11.005_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1345\/aph.1E099","article-title":"Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa","volume":"39","author":"Drobnic","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ccm.2015.11.005_bib43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A\u00a0randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib44","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib45","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib46","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2015.11.005_bib47","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2015.11.005_bib48","unstructured":"Aradigm Corporation. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pulmaquin in the management of chronic lung infections with Pseudomonas aeruginosa in patients with non-cystic fibrosis bronchiectasis, including 28 day open-label extension. ClinicalTrials.gov. [Internet]. NLM identifier: NCT02104245. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02104245. Accessed July 11, 2015."},{"key":"10.1016\/j.ccm.2015.11.005_bib49","unstructured":"Bayer. Randomized, double-blind, placebo-controlled, multicenter study comparing ciprofloxacin DPI 32.5 mg BID (twice a day) intermittently administered for 28 days on\/28 days off or 14 days on\/14 days off versus placebo to evaluate the time to first pulmonary exacerbation and frequency of exacerbations in\u00a0subjects with non-cystic fibrosis bronchiectasis. ClinicalTrials.gov. [Internet]. NLM identifier: NCT02106832. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02106832. Accessed July 11, 2015."},{"key":"10.1016\/j.ccm.2015.11.005_bib50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/089426802760292681","article-title":"Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction","volume":"15","author":"Daviskas","year":"2002","journal-title":"J\u00a0Aerosol Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1440-1843.2003.00454.x","article-title":"Effect of osmolality on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum","volume":"8","author":"Shibuya","year":"2003","journal-title":"Respirology"},{"key":"10.1016\/j.ccm.2015.11.005_bib52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A\u00a0controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccm.2015.11.005_bib53","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"Wark","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ccm.2015.11.005_bib54","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.rmed.2011.07.019","article-title":"Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis","volume":"105","author":"Kellett","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib55","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.rmed.2011.12.021","article-title":"The long-term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis","volume":"106","author":"Nicolson","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib56","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/thoraxjnl-2014-205587","article-title":"Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial","volume":"69","author":"Bilton","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2015.11.005_bib57","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib58","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group","volume":"113","author":"O\u2019Donnell","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2015.11.005_bib59","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1465-9921-15-44","article-title":"The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis: a randomised controlled trial","volume":"15","author":"Lee","year":"2014","journal-title":"Respir Res"},{"key":"10.1016\/j.ccm.2015.11.005_bib60","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.rmed.2012.08.004","article-title":"A\u00a0pilot study of pulmonary rehabilitation and chest physiotherapy versus chest physiotherapy alone in bronchiectasis","volume":"106","author":"Mandal","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib61","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/thx.2004.028928","article-title":"Exercise training and inspiratory muscle training in patients with bronchiectasis","volume":"60","author":"Newall","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2015.11.005_bib62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0749-3797(01)00261-6","article-title":"Current methods of the US Preventive Services Task Force: a review of the process","volume":"20","author":"Harris","year":"2001","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib63","first-page":"522","article-title":"Cystic fibrosis pulmonary guidelines: airway clearance therapies","volume":"54","author":"Flume","year":"2009","journal-title":"Respir Care"},{"key":"10.1016\/j.ccm.2015.11.005_bib64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1479972306074481","article-title":"A\u00a0randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrosis bronchiectasis","volume":"4","author":"Eaton","year":"2007","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.ccm.2015.11.005_bib65","first-page":"1210","article-title":"Forced expiratory technique, directed cough, and autogenic drainage","volume":"52","author":"Fink","year":"2007","journal-title":"Respir Care"},{"key":"10.1016\/j.ccm.2015.11.005_bib66","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.00055509","article-title":"A\u00a0randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis","volume":"34","author":"Murray","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2015.11.005_bib67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2466-13-21","article-title":"Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis","volume":"13","author":"Nicolini","year":"2013","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1191\/1479972304cd034oa","article-title":"Airway clearance in bronchiectasis: a randomized crossover trial of active cycle of breathing techniques (incorporating postural drainage and vibration) versus test of incremental respiratory endurance","volume":"1","author":"Patterson","year":"2004","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.ccm.2015.11.005_bib69","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000085363","article-title":"Airway clearance in bronchiectasis: a randomized crossover trial of active cycle of breathing techniques versus Acapella","volume":"72","author":"Patterson","year":"2005","journal-title":"Respiration"},{"key":"10.1016\/j.ccm.2015.11.005_bib70","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/thorax.57.5.446","article-title":"Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis","volume":"57","author":"Thompson","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2015.11.005_bib71","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1013-7025(09)70037-5","article-title":"Postural drainage or flutter device in conjunction with breathing and coughing compared to breathing and coughing alone in improving secretion removal and lung function in patients with acute exacerbation of bronchiectasis: a pilot study","volume":"21","author":"Tsang","year":"2003","journal-title":"Hong Kong Physiother J"},{"key":"10.1016\/j.ccm.2015.11.005_bib72","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.athoracsur.2012.01.012","article-title":"Thoracoscopic lobectomy and segmentectomy for infectious lung disease","volume":"93","author":"Mitchell","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ccm.2015.11.005_bib73","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.athoracsur.2014.04.049","article-title":"Lung resection improves the quality of life of patients with symptomatic bronchiectasis","volume":"98","author":"Vallilo","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ccm.2015.11.005_bib74","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1010-7940(01)00689-3","article-title":"Thoracoscopic lobectomy for benign disease: a single centre study on 64 cases","volume":"20","author":"Weber","year":"2001","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ccm.2015.11.005_bib75","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.athoracsur.2010.08.035","article-title":"Video-assisted thoracic surgery for bronchiectasis","volume":"91","author":"Zhang","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ccm.2015.11.005_bib76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/1874306401004020020","article-title":"Antiproteases as therapeutics to target inflammation in cystic fibrosis","volume":"4","author":"Quinn","year":"2010","journal-title":"Open Respir Med J"},{"key":"10.1016\/j.ccm.2015.11.005_bib77","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.rmed.2012.12.009","article-title":"Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis","volume":"107","author":"Stockley","year":"2013","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2015.11.005_bib78","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1073\/pnas.0511304103","article-title":"High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis","volume":"103","author":"Tirouvanziam","year":"2006","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523115001446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523115001446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:51:05Z","timestamp":1759452665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523115001446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0272523115001446"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2015.11.005","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using Cystic Fibrosis Therapies for Non\u2013Cystic Fibrosis Bronchiectasis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2015.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}